SCHEMBL6646205

SCHEMBL6646205

Cc1ccc(C(=O)Nc2ccc(CC(=O)Nc3ccccn3)cc2)c(N2CCC(C)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
MCL1 Q07820 1/20 0.49
ALDH1A1 P00352 2/20 0.46
ADRB2 P07550 1/20 0.45
ADRB1 P08588 1/20 0.45
ADRB3 P13945 1/20 0.45
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
MAPT P10636 2/20 0.43
LMNA P02545 3/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GRM4 Q14833 1/20 0.42
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6644659 0.88 NPC1 (0.55) RAB9ANPC1ALDH1A1KMT2AMEN1
SCHEMBL6643855 0.87 ALDH1A1 (0.48) RAB9ANPC1MCL1ALDH1A1ADRB2
SCHEMBL6646415 0.85 NPC1 (0.50) RAB9ANPC1MCL1ALDH1A1KMT2A
SCHEMBL6645235 0.83 GRM4 (0.50) RAB9ANPC1ALDH1A1ADRB2ADRB1
SCHEMBL6649926 0.80 OGA (0.49) RAB9ANPC1ALDH1A1ADRB2ADRB1
SCHEMBL6645079 0.80 KMT2A (0.51) RAB9ANPC1ALDH1A1KMT2AMEN1
SCHEMBL6646885 0.79 KMT2A (0.52) RAB9ANPC1ALDH1A1KMT2AMEN1
SCHEMBL6644222 0.79 ALDH1A1 (0.47) RAB9ANPC1MCL1ALDH1A1ADRB2
SCHEMBL6643270 0.79 ALDH1A1 (0.45) RAB9ANPC1ALDH1A1ADRB2ADRB1
SCHEMBL6646400 0.78 NAMPT (0.51) RAB9ANPC1ALDH1A1ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR RAB9A 3028/4885NPC1 34/4885MCL1 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.